Hepatobiliary Cancers: An Interdisciplinary Approach

lt;p>Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Pediatric Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital.  Professor Rezaei is now the Full Professor of Immunology and Vice Dean of Research and Technologies, School of Medicine, Tehran University of Medical Sciences, and the co-founder and Head of the Research Center for Immunodeficiencies. He is also the Founder of Universal Scientific Education and Research Network (USERN). Prof. Rezaei has already been the Director of more than 100 research projects and has designed and participated in several international collaborative projects. Prof. Rezaei is the editor, editorial assistant, or editorial board member of more than 40 international journals. He has edited more than 50 international books, has presented more than 500 lectures/posters in congresses/meetings, and has published more than 1,200 scientific papers in the international journals.

Interdisciplinary Approach in Hepatobiliary Cancers.- Liver Cancer: Interdisciplinary Approach.- The Immune System in Liver Cancer: From Beginning to Progression.- The Tumor Microenvironment in Hepatocellular Carcinoma.- Metabolic Alterations of Hepatocellular Cancer Stem Cells.- he Role of Senescence in NASH-related HCC.- Regulators of Genetic Risk for the Progression of Non-alcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Reconstruction of Transcriptional Network and Signature-Based Metabolic Profiling.- Tumor Microenvironment and Immunotherapy in Advanced Biliary Tract Cancers.- Fibrosis and Immunotherapy in Hepatocellular Carcinoma.- Liver Cancer and the Curative Potential of Nanomedicine.- Locoregional Therapies for Hepatocellular Carcinoma.- Drug Resistance in Hepatocellular Carcinoma.- Liver Stereotactic Body Radiotherapy.